6 results match your criteria: "Main Line Heart Center[Affiliation]"
The tale of the wandering circumflex.
Eur Heart J Cardiovasc Imaging
November 2012
Lankenau Medical Center, Main Line Heart Center, 558 Lankenau MOB East, 100 Lancaster avenue, Wynnewood, PA 19096, USA.
Preface Advances in Antiarrhythmic Drug Therapy.
Card Electrophysiol Clin
September 2010
MSHMC Cardiology, 500 University Drive, Hershey, PA 17033-0850, USA.
Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval.
Circ Heart Fail
July 2010
Main Line Heart Center and Lankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, Pa 19096, USA.
Drug therapy for atrial fibrillation.
Cardiol Clin
February 2009
Lankenau Hospital, Division of Cardiovascular Diseases, Main Line Heart Center, Suite 556, Medical Office Building East, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.
Atrial fibrillation is the most frequently diagnosed arrhythmia. Prevalence increases with age, and the overall incidence is expected to increase as the population continues to age. Choice of pharmacologic therapy for atrial fibrillation depends on whether or not the goal of treatment is maintaining sinus rhythm or tolerating atrial fibrillation with adequate control of ventricular rates.
View Article and Find Full Text PDFDrug therapy for atrial fibrillation.
Med Clin North Am
January 2008
Division of Cardiovascular Diseases, Main Line Heart Center, 556 Medical Office, Building East, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.
Atrial fibrillation (AF) is the most frequently diagnosed arrhythmia. Prevalence increases with age, and the overall incidence is expected to increase as the population continues to age. Choice of pharmacologic therapy for atrial fibrillation depends on whether or not the goal of treatment is maintaining sinus rhythm or tolerating atrial fibrillation with adequate control of ventricular rates.
View Article and Find Full Text PDFFuture directions in antiarrhythmic drug therapy for atrial fibrillation.
Future Cardiol
September 2006
Division of Cardiovascular Diseases, Main Line Heart Center, 556 Medical Science Building, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.
Atrial fibrillation is the most commonly sustained cardiac arrhythmia. Drugs currently approved by the US FDA for the treatment of this arrhythmia are imperfect owing to either side effects or limited efficacy. Drug development strategies have focused on two areas: the modification of existing agents--such as Class III drugs aimed at improving their safety and efficacy profile--and targeting newly postulated mechanisms of atrial fibrillation.
View Article and Find Full Text PDF